Officials to test water from Ohio village near Cold War-era weapons plant after newspaper probe
Authorities in Ohio plan to test the groundwater supply across a village near a former weapons plant after a newspaper investigation published Friday found high levels of radioactivity in samples taken at a school, athletic field, library and other sites.
The Army Corps of Engineers has been removing tons of contaminated soil from the Cold War-era site since 2018 and has long maintained that residential areas were not affected by the work.
However, The Blade in Toledo said its tests showed radioactivity levels 10 times higher than normal in water from a drinking fountain at Eastwood Middle School, 45 times higher than normal at the Luckey Library and 1,731 times higher than normal at a water pump near athletic fields.
"We've got to get to the bottom of this," said Lt. Col. Robert Burnham, commander of the U.S. Army Corps of Engineers' Buffalo District, which oversees the cleanup.
Nineteen of the 39 samples collected by the newspaper from well water across Luckey — at homes, businesses, and public places — showed radioactivity at least 10 times greater than what the federal government calls normal for the area, the newspaper said. The Blade hired an accredited private lab to conduct the testing.
The radioactivity detected was primarily bismuth-214, which decays from the radioactive gas radon-222. Experts agree that high levels of bismuth-214 suggest high radon levels are also present.
Radon exposure is the leading cause of lung cancer in nonsmokers.
The testing also found low levels of radioactive cobalt-60, a man-made isotope, in two wells. Experts called that finding extremely rare.
Taehyun Roh, a Texas A&M University scientist who specializes in environmental exposures, said regulators should also conduct air and soil testing to assess the extent of the contamination and identify the source.
"Since this area likely has high radon levels, testing for radon in both air and water is advisable," he wrote in an email. "A safe drinking water advisory should be issued, recommending the use of bottled water until further assessments and mitigation measures are in place."
The Corps of Engineers has long maintained that residential drinking water was not being contaminated by the removal work. Burnham and others said they still believe that to be true, citing thousands of their own soil samples.
The state Environmental Protection Agency and Department of Health will lead the testing. In an email, Ohio EPA spokesperson Katie Boyer told the newspaper the contaminant levels in the public drinking water are still "within acceptable drinking water standards." She said any concerns raised by the state testing would be addressed.
The 44-acre industrial site — 22 miles (35 kilometers) south of Toledo — was long crucial to America's nuclear weapons program. In the 1940s, farmland was replaced by a sprawling defense plant that produced magnesium metal for the Manhattan Project. In the 1950s, the plant became the government's sole source of beryllium metal for nuclear bombs, Cold War missiles and Space Race products, including a heat shield for Project Mercury.
"Things that happened generations ago are still affecting us," said Karina Hahn-Claydon, a 50-year-old teacher whose family lives less than a mile from the site. "And that's because the government didn't take care of it."
Private drinking wells, unlike municipal systems, are not regulated, and responsibility for testing is left to owners. The Blade's testing took place from April 2024 through January.
Radioactivity has been linked to an increased risk of various cancers, including blood and thyroid cancers.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Opinion: How Much More Positive Head Start Evidence Do We Need to Save It?
The Trump administration's first four months have been rough on U.S. children. They certainly don't deserve the punishment. From polarized and destabilizing politics to a global pandemic, increasing environmental pressures from climate change (and more), this cohort of children is coming of age in a particularly difficult moment. And yet, we have reached what is perhaps a zenith in Trump-era politics of disinvesting in children and families. The administration's response to America's youth crisis has been stunningly consistent: again and again, it has balanced occasional, vague promises to do something constructive to address child care costs or infertility challenges on the one hand with real and stunningly concrete attacks on children's well-being on the other. Get stories like this delivered straight to your inbox. Sign up for The 74 Newsletter Perhaps the most direct and comprehensive assault on children is coming through the administration's war on Head Start. At $12.3 billion last year, it's the federal government's largest-single investment in early learning, and it serves almost 800,000 children and families per year. Over its 60 years, Head Start has provided high-quality early learning as well as connecting around 40 million children and their families to comprehensive support services like health and dental care, nutrition and housing assistance. During the 2024 campaign, Donald Trump echoed the Heritage Foundation's Project 2025 playbook in calling for Head Start's elimination. This was hardly novel: though Head Start has long enjoyed bipartisan support, a subset of conservative researchers, activists and politicians have spent decades attacking the program. While the administration's chaotic first 100 days decimated portions of the federal government supporting health and well-being, its attacks on Head Start have been uniquely unpredictable. In January, as Elon Musk and his underlings at the Department of Government Efficiency hacked away at the federal civil service, Head Start providers across the country reported that they were unable to access their normally scheduled federal payments. This posed a particular challenge for Head Start center directors navigating the tight margins that define the early education market; hundreds of early care and learning centers warned that they were at risk of closure. Related Later in the spring, the administration abruptly pulled funding from regional Head Start centers that offer resources, support and oversight for Head Start providers. Several weeks ago, it appeared that the administration was preparing to act more decisively to abandon U.S. kids and families who depend on Head Start. On April 17, the Associated Press reported on leaked documents indicating that the Trump administration would erase Head Start funding in its forthcoming budget proposal. Once this hit the news, Head Start supporters mobilized to save the program, and the administration reversed course. While it appears that the administration isn't (yet) ready to deliver on this promised assault on children's well-being, it's worth reminding ourselves just what a stunning mistake it would be to reduce this particular investment in U.S. kids and families. Related Head Start has been studied many times, and the results are broadly positive. Research on it — and other early education programs — finds a relatively consistent pattern: Early education programs are reliably good for families and at preparing kids for kindergarten There's some waning of positive academic impacts as kids go through K-12 But the long-term impacts of early ed investments are generally positive. First, Head Start appears to be particularly effective at helping children from historically marginalized communities. Perhaps most importantly in the present political context, early education programs tend to promote better child development outcomes that create cost savings for school budgets. This mostly results from pre-K programs like Head Start reducing the likelihood that children will later require special education services or need to repeat a grade. For instance, economist Tim Bartik notes that studies show possible special education cost-savings of '23 to 86 percent.' Meanwhile, if a child repeats second (or any) grade, the public pays an additional year of per-pupil funding, and it also delays their entry into the workforce. As such, pre-K's ability to lower grade retention and keep students on track for college and career is a particularly efficient return on early education investments. Finally, early education programs like Head Start are a boon for working families because they help parents get back to work sooner after having a child. Most encouraging of all, Head Start appears to create some long-term positive effects. In 2022, researchers at the University of Notre Dame and Texas A&M found that the children of Head Start participants garnered benefits like higher high school graduation and college attainment rates, lower rates of teen pregnancy and reduced rates of interaction with the criminal justice system. For instance, critics often point to the federal Head Start Impact Study, which gathered data on programs in the early 2000s. It largely found that Head Start had positive initial effects on children's development, but that these effects 'faded out' as kids worked their way into the K–12 education system. But problems with the study's data prompted a field reassessment of its findings in the 2010s, with most researchers concluding that it meaningfully underestimated Head Start's benefits to children. This begs some critical questions about how the public should measure 'success' for Head Start. Begin here: nearly every study of nearly every early education investment shows that these programs are effective at getting kids ready for K–12 schooling. Put simply, pre-K appears to be good at getting kids 'pre'-pared for K(indergarten). Related The trouble is, political rhetoric about early education investments has sometimes presented them as an invulnerable 'inoculation' against all challenges that children may face later in life. This is the wrong way to think about whether early education investments 'work,' because it sets an impossible bar for success. Head Start — or pre-K programs more generally — cannot wholly blunt poverty, poor health or the impacts of low-quality K–12 classrooms. Indeed, even less rosy findings, like those in a recent study of Tennessee's public pre-K program, indicate a positive path forward for public early education investments. Initial studies of the program garnered headlines. While Tennessee pre-K attendees were generally more ready for kindergarten than their peers who did not attend the program, pre-K attendees scored worse on a range of metrics by the end of elementary school. This is concerning! But a more recent analysis of Tennessee's data found that pre-K's benefits were 'most likely to persist until 3rd grade among those students who went on to attend high quality schooling environments and were taught by highly effective teachers.' That is, Tennessee's pre-K programs succeeded at preparing children for kindergarten, and kids who went from those programs into higher-quality elementary classrooms continued to do better. In other words, if Head Start and other pre-K programs are measured as a one-time public investment that will solve all systemic inequities in American schools and society, they will inevitably appear to fail. But if they are measured against their ability to prepare children for elementary schools, it is clear that they are a success. Furthermore, this fairer definition of Head Start's effectiveness would allow policymakers to focus their attention on the necessary work of investing and improving K–12 schools so that they bolster children and families beyond the early years.
Yahoo
2 hours ago
- Yahoo
Jade Biosciences Presents JADE101 Preclinical Data at the 62nd European Renal Association Congress Demonstrating Potential for Best-in-Class Profile in IgA Nephropathy
SAN FRANCISCO and VANCOUVER, British Columbia, June 09, 2025 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. ('Jade') (Nasdaq: JBIO), a biotechnology company focused on developing best-in-class therapies for autoimmune diseases, today announced a detailed preclinical characterization of JADE101, its anti-A Proliferation-Inducing Ligand (APRIL) monoclonal antibody, in development for IgA nephropathy (IgAN), a chronic autoimmune kidney disease. The findings, presented during an oral session at the 62nd European Renal Association (ERA) Congress, support advancement of JADE101 into a planned healthy volunteer study in the second half of 2025. 'IgA nephropathy often begins in young adulthood and typically requires lifelong treatment, yet current treatment options have limitations in efficacy and ease of use,' said Andrew King, BVMS, Ph.D., Chief Scientific Officer and Head of R&D at Jade Biosciences. 'Jade's preclinical data presented at ERA demonstrate JADE101's potential to be a best-in-class disease-modifying therapy. JADE101 has the potential to fully capture the efficacy available to the anti-APRIL mechanism with convenient, infrequent dosing. We believe this profile could translate into meaningful long-term benefit for patients, and we look forward to advancing this promising candidate into the clinic later this year.' Summary of Jade Biosciences' ERA 2025 Presentation Jade's presentation at ERA focused on a comprehensive preclinical characterization of JADE101, a fully human monoclonal antibody targeting APRIL, designed to address key limitations of earlier molecules in this class. JADE101 incorporates a YTE-modified IgG1 backbone and was engineered to improve target affinity, extend pharmacokinetic exposure, and reduce risks associated with immune complex formation and rapid clearance. The molecular design of JADE101 prolonged systemic exposure that delivers sustained target engagement, with a goal of supporting clinical dosing intervals of eight weeks or potentially longer. JADE101 was compared with sibeprenlimab, an investigational late-stage anti-APRIL monoclonal antibody, manufactured from publicly available sequences. A YTE-engineered version of sibeprenlimab was also tested to isolate the impact of Fc modification on pharmacokinetic profiles in non-human primates (NHPs). Key findings included: Ultra-high APRIL binding affinityJADE101 binds APRIL with femtomolar affinity (approximately 50 fM), over 750-fold higher affinity than sibeprenlimab. This higher binding affinity has the potential to enable complete suppression of APRIL at low plasma concentrations of JADE101 to deliver the full efficacy available to the anti-APRIL mechanism and further support an extended dosing interval. Potent inhibition of APRIL signaling through BCMA and TACIJADE101 demonstrated potent blockade of APRIL binding and signaling through its receptors in in vitro assays, including assays designed to model mechanistic aspects of the therapeutic benefit of APRIL inhibition in IgAN. In competitive binding assays, JADE101 fully inhibited APRIL binding to its receptors BCMA and TACI with IC50 values of 1.9 nM and 1.03 nM, respectively. In cell-based reporter assays, JADE101 blocked APRIL-induced signaling through BCMA (IC50 = 5.97 nM) and TACI (IC50 = 0.22 nM). JADE101 also potently reduced human plasma cell proliferation and IgA secretion in vitro. Extended pharmacokinetics and deep, sustained IgA suppression in NHPsIn NHPs, a single 30 mg/kg intravenous dose of JADE101 demonstrated an approximately 27-day half-life, nearly 4 times longer than sibeprenlimab at the same dose, and maintained linear clearance down to approximately 2 µg/mL, well below the approximately 40 µg/mL target-mediated drug disposition (TMDD) threshold observed for sibeprenlimab. This pharmacokinetic profile translated into sustained IgA suppression for more than 100 days after a single 30 mg/kg dose in NHPs. Notably, JADE101 dosed at just 4 mg/kg (7.5-fold lower) achieved deeper and more durable IgA reductions in NHPs than both sibeprenlimab and YTE-modified sibeprenlimab dosed at 30 mg/kg. Favorable subcutaneous profile in NHPsFollowing a single 100 mg/kg subcutaneous dose, JADE101 exhibited high bioavailability and a linear half-life exceeding 30 days in NHPs, supporting the potential for convenient, infrequent subcutaneous dosing in clinical settings. Designed to reduce risk of high molecular weight immune complex formationJADE101 binds a novel epitope on trimeric APRIL and was specifically selected to avoid the formation of high molecular weight immune complexes, that can occur with the first-generation anti-APRIL monoclonal antibodies. Immune complexes have potential to be associated with an increased risk of immunogenicity and tissue deposition, and to result in accelerated drug clearance. By avoiding their formation, JADE101 may mitigate these risks, supporting more consistent pharmacokinetics and sustained exposure over time. Jade plans to initiate a study of JADE101 in healthy volunteers in the second half of 2025. The study will evaluate safety, tolerability, pharmacokinetics, pharmacodynamics, and suppression of key biomarkers including APRIL and IgA. Interim data are expected in the first half of 2026 and are anticipated to guide dose and dose interval selection for future JADE101 studies in patients with IgAN. Conference Call and Webcast Jade Biosciences will host a conference call and webcast today, Monday, June 9, 2025, at 8:00 a.m. ET to review the JADE101 data presented at ERA 2025. Investors and the public are invited to join the live webcast by registering on the 'Events and Presentations' page of To join the conference call, participants must register here. Upon registering, dial-in details and a unique PIN will be provided. A replay of the webcast will be available shortly after the call concludes. About IgA nephropathy (IgAN) IgAN is a chronic autoimmune kidney disease that affects approximately 169,000 people in the U.S. and is most often diagnosed in young adults. The disease is characterized by the deposition of pathogenic IgA-containing immune complexes in the kidneys. These deposits can lead to increased protein in the urine, also known as proteinuria, declining kidney function, and potentially end-stage kidney disease requiring dialysis or a transplant. IgAN often requires lifelong treatment to preserve kidney function and prevent progression to kidney failure. About JADE101 JADE101 is an anti-APRIL monoclonal antibody being developed for the treatment of IgAN. By targeting APRIL, a protein involved in the overproduction of IgA, JADE101 aims to reduce the levels of disease-driving IgA, decrease proteinuria, and preserve kidney function. Engineered with half-life extension technology, JADE101 is designed for dosing at intervals of at least eight weeks, offering the potential for durable clinical activity and improved patient convenience, particularly important for a condition often diagnosed in young adulthood and potentially requiring life-long treatment. About Jade Biosciences, Inc. Jade Biosciences is focused on developing best-in-class therapies to address critical unmet needs in autoimmune diseases. Its lead candidate, JADE101, targets the cytokine APRIL for the treatment of immunoglobulin A nephropathy, with initiation of a first-in-human clinical trial expected in the second half of 2025. Jade's pipeline also includes a second development candidate, JADE201, and an undisclosed antibody discovery program, JADE-003, both currently in preclinical development. Jade was launched based on assets licensed from Paragon Therapeutics, an antibody discovery engine founded by Fairmount. For more information, visit and follow the Company on LinkedIn. Forward-Looking Statements Certain statements in this communication, other than purely historical information, may constitute "forward-looking statements" within the meaning of the federal securities laws, including for purposes of the "safe harbor" provisions under the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, express or implied statements relating to Jade's expectations, hopes, beliefs, intentions or strategies regarding the future of its pipeline and business including, without limitation, Jade's ability to achieve the expected benefits or opportunities with respect to JADE101, JADE201 and the JADE-003 program, including without limitation the expected timelines for JADE101 entering the clinic and interim data from such trial, the potential of Jade's product candidates to become best-in-class therapies and their potential therapeutic uses, efficacy, dosing, safety and market opportunities. The words "opportunity," "potential," "milestones," "pipeline," "can," "goal," "strategy," "target," "anticipate," "achieve," "believe," "contemplate," "continue," "could," "estimate," "expect," "intends," "may," "plan," "possible," "project," "should," "will," "would" and similar expressions (including the negatives of these terms or variations of them) may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements are based on current expectations and beliefs concerning future developments and their potential effects. There can be no assurance that future developments affecting Jade will be those that have been anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond Jade's control) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, the risks that the planned trial of JADE101 and any future clinical trials may be delayed or may not demonstrate safety and/or efficacy; Jade may experience unanticipated costs, difficulties or delays in the product development process; Jade's product candidates may fail in development, may not receive required regulatory approvals, or may be delayed to a point where they are not commercially viable; regulatory agencies may impose additional requirements or delay the initiation of clinical trials; risks associated with Jade's dependence on third-party vendors for the development, manufacture and supply of JADE101; and the other risks, uncertainties and factors more fully described in Jade's most recent filings with the Securities and Exchange Commission (including the definitive proxy statement/prospectus filed on Form S-4, most recently amended on March 24, 2025 and declared effective on March 25, 2025). Should one or more of these risks or uncertainties materialize, or should any of Jade's assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. You should not place undue reliance on forward-looking statements in this communication, which speak only as of the date they are made and are qualified in their entirety by reference to the cautionary statements herein. Jade does not undertake or accept any duty to release publicly any updates or revisions to any forward-looking statements. This communication does not purport to summarize all of the conditions, risks and other attributes of an investment in Jade. Jade Biosciences Media & Investor Contacts Priyanka ShahEmail: Media@ Email: IR@ Phone: 908-447-6134Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
7 hours ago
- Yahoo
Jade Biosciences Presents JADE101 Preclinical Data at the 62nd European Renal Association Congress Demonstrating Potential for Best-in-Class Profile in IgA Nephropathy
SAN FRANCISCO and VANCOUVER, British Columbia, June 09, 2025 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. ('Jade') (Nasdaq: JBIO), a biotechnology company focused on developing best-in-class therapies for autoimmune diseases, today announced a detailed preclinical characterization of JADE101, its anti-A Proliferation-Inducing Ligand (APRIL) monoclonal antibody, in development for IgA nephropathy (IgAN), a chronic autoimmune kidney disease. The findings, presented during an oral session at the 62nd European Renal Association (ERA) Congress, support advancement of JADE101 into a planned healthy volunteer study in the second half of 2025. 'IgA nephropathy often begins in young adulthood and typically requires lifelong treatment, yet current treatment options have limitations in efficacy and ease of use,' said Andrew King, BVMS, Ph.D., Chief Scientific Officer and Head of R&D at Jade Biosciences. 'Jade's preclinical data presented at ERA demonstrate JADE101's potential to be a best-in-class disease-modifying therapy. JADE101 has the potential to fully capture the efficacy available to the anti-APRIL mechanism with convenient, infrequent dosing. We believe this profile could translate into meaningful long-term benefit for patients, and we look forward to advancing this promising candidate into the clinic later this year.' Summary of Jade Biosciences' ERA 2025 Presentation Jade's presentation at ERA focused on a comprehensive preclinical characterization of JADE101, a fully human monoclonal antibody targeting APRIL, designed to address key limitations of earlier molecules in this class. JADE101 incorporates a YTE-modified IgG1 backbone and was engineered to improve target affinity, extend pharmacokinetic exposure, and reduce risks associated with immune complex formation and rapid clearance. The molecular design of JADE101 prolonged systemic exposure that delivers sustained target engagement, with a goal of supporting clinical dosing intervals of eight weeks or potentially longer. JADE101 was compared with sibeprenlimab, an investigational late-stage anti-APRIL monoclonal antibody, manufactured from publicly available sequences. A YTE-engineered version of sibeprenlimab was also tested to isolate the impact of Fc modification on pharmacokinetic profiles in non-human primates (NHPs). Key findings included: Ultra-high APRIL binding affinityJADE101 binds APRIL with femtomolar affinity (approximately 50 fM), over 750-fold higher affinity than sibeprenlimab. This higher binding affinity has the potential to enable complete suppression of APRIL at low plasma concentrations of JADE101 to deliver the full efficacy available to the anti-APRIL mechanism and further support an extended dosing interval. Potent inhibition of APRIL signaling through BCMA and TACIJADE101 demonstrated potent blockade of APRIL binding and signaling through its receptors in in vitro assays, including assays designed to model mechanistic aspects of the therapeutic benefit of APRIL inhibition in IgAN. In competitive binding assays, JADE101 fully inhibited APRIL binding to its receptors BCMA and TACI with IC50 values of 1.9 nM and 1.03 nM, respectively. In cell-based reporter assays, JADE101 blocked APRIL-induced signaling through BCMA (IC50 = 5.97 nM) and TACI (IC50 = 0.22 nM). JADE101 also potently reduced human plasma cell proliferation and IgA secretion in vitro. Extended pharmacokinetics and deep, sustained IgA suppression in NHPsIn NHPs, a single 30 mg/kg intravenous dose of JADE101 demonstrated an approximately 27-day half-life, nearly 4 times longer than sibeprenlimab at the same dose, and maintained linear clearance down to approximately 2 µg/mL, well below the approximately 40 µg/mL target-mediated drug disposition (TMDD) threshold observed for sibeprenlimab. This pharmacokinetic profile translated into sustained IgA suppression for more than 100 days after a single 30 mg/kg dose in NHPs. Notably, JADE101 dosed at just 4 mg/kg (7.5-fold lower) achieved deeper and more durable IgA reductions in NHPs than both sibeprenlimab and YTE-modified sibeprenlimab dosed at 30 mg/kg. Favorable subcutaneous profile in NHPsFollowing a single 100 mg/kg subcutaneous dose, JADE101 exhibited high bioavailability and a linear half-life exceeding 30 days in NHPs, supporting the potential for convenient, infrequent subcutaneous dosing in clinical settings. Designed to reduce risk of high molecular weight immune complex formationJADE101 binds a novel epitope on trimeric APRIL and was specifically selected to avoid the formation of high molecular weight immune complexes, that can occur with the first-generation anti-APRIL monoclonal antibodies. Immune complexes have potential to be associated with an increased risk of immunogenicity and tissue deposition, and to result in accelerated drug clearance. By avoiding their formation, JADE101 may mitigate these risks, supporting more consistent pharmacokinetics and sustained exposure over time. Jade plans to initiate a study of JADE101 in healthy volunteers in the second half of 2025. The study will evaluate safety, tolerability, pharmacokinetics, pharmacodynamics, and suppression of key biomarkers including APRIL and IgA. Interim data are expected in the first half of 2026 and are anticipated to guide dose and dose interval selection for future JADE101 studies in patients with IgAN. Conference Call and Webcast Jade Biosciences will host a conference call and webcast today, Monday, June 9, 2025, at 8:00 a.m. ET to review the JADE101 data presented at ERA 2025. Investors and the public are invited to join the live webcast by registering on the 'Events and Presentations' page of To join the conference call, participants must register here. Upon registering, dial-in details and a unique PIN will be provided. A replay of the webcast will be available shortly after the call concludes. About IgA nephropathy (IgAN) IgAN is a chronic autoimmune kidney disease that affects approximately 169,000 people in the U.S. and is most often diagnosed in young adults. The disease is characterized by the deposition of pathogenic IgA-containing immune complexes in the kidneys. These deposits can lead to increased protein in the urine, also known as proteinuria, declining kidney function, and potentially end-stage kidney disease requiring dialysis or a transplant. IgAN often requires lifelong treatment to preserve kidney function and prevent progression to kidney failure. About JADE101 JADE101 is an anti-APRIL monoclonal antibody being developed for the treatment of IgAN. By targeting APRIL, a protein involved in the overproduction of IgA, JADE101 aims to reduce the levels of disease-driving IgA, decrease proteinuria, and preserve kidney function. Engineered with half-life extension technology, JADE101 is designed for dosing at intervals of at least eight weeks, offering the potential for durable clinical activity and improved patient convenience, particularly important for a condition often diagnosed in young adulthood and potentially requiring life-long treatment. About Jade Biosciences, Inc. Jade Biosciences is focused on developing best-in-class therapies to address critical unmet needs in autoimmune diseases. Its lead candidate, JADE101, targets the cytokine APRIL for the treatment of immunoglobulin A nephropathy, with initiation of a first-in-human clinical trial expected in the second half of 2025. Jade's pipeline also includes a second development candidate, JADE201, and an undisclosed antibody discovery program, JADE-003, both currently in preclinical development. Jade was launched based on assets licensed from Paragon Therapeutics, an antibody discovery engine founded by Fairmount. For more information, visit and follow the Company on LinkedIn. Forward-Looking Statements Certain statements in this communication, other than purely historical information, may constitute "forward-looking statements" within the meaning of the federal securities laws, including for purposes of the "safe harbor" provisions under the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, express or implied statements relating to Jade's expectations, hopes, beliefs, intentions or strategies regarding the future of its pipeline and business including, without limitation, Jade's ability to achieve the expected benefits or opportunities with respect to JADE101, JADE201 and the JADE-003 program, including without limitation the expected timelines for JADE101 entering the clinic and interim data from such trial, the potential of Jade's product candidates to become best-in-class therapies and their potential therapeutic uses, efficacy, dosing, safety and market opportunities. The words "opportunity," "potential," "milestones," "pipeline," "can," "goal," "strategy," "target," "anticipate," "achieve," "believe," "contemplate," "continue," "could," "estimate," "expect," "intends," "may," "plan," "possible," "project," "should," "will," "would" and similar expressions (including the negatives of these terms or variations of them) may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements are based on current expectations and beliefs concerning future developments and their potential effects. There can be no assurance that future developments affecting Jade will be those that have been anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond Jade's control) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, the risks that the planned trial of JADE101 and any future clinical trials may be delayed or may not demonstrate safety and/or efficacy; Jade may experience unanticipated costs, difficulties or delays in the product development process; Jade's product candidates may fail in development, may not receive required regulatory approvals, or may be delayed to a point where they are not commercially viable; regulatory agencies may impose additional requirements or delay the initiation of clinical trials; risks associated with Jade's dependence on third-party vendors for the development, manufacture and supply of JADE101; and the other risks, uncertainties and factors more fully described in Jade's most recent filings with the Securities and Exchange Commission (including the definitive proxy statement/prospectus filed on Form S-4, most recently amended on March 24, 2025 and declared effective on March 25, 2025). Should one or more of these risks or uncertainties materialize, or should any of Jade's assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. You should not place undue reliance on forward-looking statements in this communication, which speak only as of the date they are made and are qualified in their entirety by reference to the cautionary statements herein. Jade does not undertake or accept any duty to release publicly any updates or revisions to any forward-looking statements. This communication does not purport to summarize all of the conditions, risks and other attributes of an investment in Jade. Jade Biosciences Media & Investor Contacts Priyanka ShahEmail: Media@ Email: IR@ Phone: 908-447-6134登入存取你的投資組合
